Celcuity Strengthens Board with Biotech Veteran Gryska Amid Commercial Push
Event summary
- Celcuity Inc. appointed David W. Gryska to its Board of Directors on October 2, 2026.
- Gryska brings over 35 years of strategic and financial leadership experience in the life sciences industry.
- Gryska previously served as CFO at Incyte Corporation and Celgene Corporation.
- Celcuity recently received its first FDA approval for REVTORPYK™ (gedatolisib).
- Gryska's appointment follows the company's transition into a commercial-stage company.
The big picture
Celcuity's appointment of David Gryska to its Board of Directors underscores its strategic pivot from clinical development to commercialization following the FDA approval of REVTORPYK. Gryska's extensive experience in scaling biotech companies positions Celcuity to navigate the complexities of launching a new therapy in a competitive oncology market. The move highlights the company's focus on strengthening governance to support its transition into a commercial-stage entity.
What we're watching
- Commercial Execution
- How Celcuity will leverage Gryska's experience to scale REVTORPYK's launch and commercialization efforts.
- Clinical Development
- Whether the company can sustain momentum in advancing gedatolisib for additional solid tumor indications.
- Board Influence
- The pace at which Gryska's strategic insights will impact Celcuity's long-term growth capabilities.
Related topics